Is TuHURA Biosciences, Inc./NV (HURA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 14.9% / 30% | 0.5% / 30% | N/A | ✓ HALAL |
| DJIM | 0.2% / 33% | 14.9% / 33% | 0.5% / 33% | N/A | ✓ HALAL |
| MSCI | 1.0% / 33% | 63.4% / 33% | 2.2% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 14.9% / 33% | 0.5% / 33% | N/A | ✓ HALAL |
| FTSE | 1.0% / 33% | 63.4% / 33% | 2.2% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -418.1% | |
| Return on Assets (ROA) | -60.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$15M |
| Free Cash Flow | -$15M |
| Total Debt | $202,542 |
| Debt-to-Equity | 4.2 |
| Current Ratio | 0.4 |
| Total Assets | $20M |
Price & Trading
| Last Close | $1.95 |
| 50-Day MA | $1.29 |
| 200-Day MA | $1.97 |
| Avg Volume | 1.7M |
|
52-Week Range
$0.41
| |
About TuHURA Biosciences, Inc./NV (HURA)
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is TuHURA Biosciences, Inc./NV (HURA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), TuHURA Biosciences, Inc./NV is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is TuHURA Biosciences, Inc./NV's debt ratio?
TuHURA Biosciences, Inc./NV's debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.0%.
What are TuHURA Biosciences, Inc./NV's key financial metrics?
TuHURA Biosciences, Inc./NV has a market capitalization of $102M. Return on equity stands at -418.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.